Treatment of pituitary dwarfism with authentic recombinant human growth hormone (SM-9500).
Twenty-one patients with pituitary dwarfism were treated with methionine-free hGH (r-hGH) for 6 months with a dosage of 0.5 IU/kg/week. The height of newly treated patients (N = 14), increased from 2.4 to 5.0 cm during treatment, which corresponded to from 4.8 to 10.0 cm with a mean of 8.1 +/- 0.5 cm/year. In switched patients (N = 7), height increased from 2.2 to 3.8 cm during the treatment, which corresponded to 4.4-7.6 cm with a mean of 6.1 +/- 0.5 cm/year, which was similar to that observed in previous treatment with pituitary extracted hGH (p-hGH). Anti-hGH antibody was observed in two patients (9.5%) at the end of 6 months of treatment with a titer of 10. These data indicate that r-hGH has a growth promoting effect and low antigenicity.
D000293:Adolescent; D000365:Age Determination by Skeleton; D000906:Antibodies / Q000032:analysis; D002648:Child; D004393:Dwarfism, Pituitary / Q000188:drug therapy*; D005260:Female; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000172:deficiency / Q000276:immunology; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
D000906:Antibodies; D006728:Hormones; D011994:Recombinant Proteins; D013006:Growth Hormone